STOCK TITAN

[8-K] Torrid Holdings Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Form 4 snapshot: On 08/01/2025 Silvercape Investments Ltd—classified as a 10% owner of PetMed Express (PETS)—purchased 118,200 common shares at $3.21, an outlay of roughly $379 k. Following the trade, Silvercape’s direct holding rises to 2,478,696 shares. No sales, derivative transactions or Rule 10b5-1 plan designations were disclosed. Insider buying of this magnitude by a large holder is typically read as a vote of confidence in future prospects and strengthens shareholder alignment.

Riepilogo Modulo 4: Il 01/08/2025 Silvercape Investments Ltd—classificata come detentrice del 10% di PetMed Express (PETS)—ha acquistato 118.200 azioni ordinarie al prezzo di 3,21 $, per un investimento di circa 379.000 $. Dopo l'operazione, la partecipazione diretta di Silvercape sale a 2.478.696 azioni. Non sono state comunicate vendite, transazioni su derivati o designazioni di piani secondo la Regola 10b5-1. L'acquisto di insider di questa entità da parte di un grande azionista è generalmente interpretato come un segnale di fiducia nelle prospettive future e rafforza l'allineamento con gli azionisti.

Resumen del Formulario 4: El 01/08/2025 Silvercape Investments Ltd—clasificada como propietaria del 10% de PetMed Express (PETS)—compró 118,200 acciones comunes a $3.21, con un desembolso aproximado de $379,000. Tras la operación, la participación directa de Silvercape aumenta a 2,478,696 acciones. No se divulgaron ventas, transacciones de derivados ni designaciones bajo el plan de la Regla 10b5-1. La compra de acciones por parte de un insider de esta magnitud por un gran accionista suele interpretarse como una señal de confianza en las perspectivas futuras y fortalece la alineación con los accionistas.

폼 4 요약: 2025년 8월 1일, PetMed Express (PETS)의 10% 소유주로 분류된 Silvercape Investments Ltd가 보통주 118,200주를 $3.21에 매수하여 약 $379,000를 지출했습니다. 거래 후 Silvercape의 직접 보유 주식 수는 2,478,696주로 증가했습니다. 매도, 파생상품 거래 또는 Rule 10b5-1 계획 지정은 공개되지 않았습니다. 대규모 보유자의 이 정도 규모의 내부자 매수는 일반적으로 미래 전망에 대한 신뢰의 표시로 해석되며 주주 간의 일치를 강화합니다.

Résumé du formulaire 4 : Le 01/08/2025, Silvercape Investments Ltd—classée comme détentrice de 10 % de PetMed Express (PETS)—a acheté 118 200 actions ordinaires à 3,21 $, pour un investissement d'environ 379 000 $. Suite à cette opération, la participation directe de Silvercape s'élève à 2 478 696 actions. Aucune vente, transaction sur dérivés ou désignation de plan selon la règle 10b5-1 n'a été divulguée. Un achat d'initié de cette ampleur par un grand actionnaire est généralement interprété comme un signe de confiance dans les perspectives futures et renforce l'alignement avec les actionnaires.

Formular 4 Übersicht: Am 01.08.2025 kaufte Silvercape Investments Ltd—eingestuft als 10%-Eigentümer von PetMed Express (PETS)—118.200 Stammaktien zum Preis von 3,21 $, was einen Aufwand von etwa 379.000 $ bedeutet. Nach dem Handel steigt Silvercapes Direktbeteiligung auf 2.478.696 Aktien. Es wurden keine Verkäufe, Derivatgeschäfte oder Regel 10b5-1 Planbezeichnungen offengelegt. Insider-Käufe dieser Größenordnung durch einen Großaktionär werden typischerweise als Vertrauensbeweis in die zukünftigen Aussichten gewertet und stärken die Aktionärsausrichtung.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 10% owner buys 118k PETS shares for $379k, lifting stake to 2.48 M; signals insider confidence and modestly positive sentiment.

The purchase represents a 4.8% addition to Silvercape’s existing position, executed well below PETS’ historical averages, suggesting perceived undervaluation. With no offsetting sales or hedges, the transaction is unambiguously bullish. While the dollar amount is not transformational, accumulation by a control-level shareholder often precedes strategic initiatives or expectations of operational improvement. For investors, the filing marginally improves the risk-reward profile and may provide near-term support to the share price.

Riepilogo Modulo 4: Il 01/08/2025 Silvercape Investments Ltd—classificata come detentrice del 10% di PetMed Express (PETS)—ha acquistato 118.200 azioni ordinarie al prezzo di 3,21 $, per un investimento di circa 379.000 $. Dopo l'operazione, la partecipazione diretta di Silvercape sale a 2.478.696 azioni. Non sono state comunicate vendite, transazioni su derivati o designazioni di piani secondo la Regola 10b5-1. L'acquisto di insider di questa entità da parte di un grande azionista è generalmente interpretato come un segnale di fiducia nelle prospettive future e rafforza l'allineamento con gli azionisti.

Resumen del Formulario 4: El 01/08/2025 Silvercape Investments Ltd—clasificada como propietaria del 10% de PetMed Express (PETS)—compró 118,200 acciones comunes a $3.21, con un desembolso aproximado de $379,000. Tras la operación, la participación directa de Silvercape aumenta a 2,478,696 acciones. No se divulgaron ventas, transacciones de derivados ni designaciones bajo el plan de la Regla 10b5-1. La compra de acciones por parte de un insider de esta magnitud por un gran accionista suele interpretarse como una señal de confianza en las perspectivas futuras y fortalece la alineación con los accionistas.

폼 4 요약: 2025년 8월 1일, PetMed Express (PETS)의 10% 소유주로 분류된 Silvercape Investments Ltd가 보통주 118,200주를 $3.21에 매수하여 약 $379,000를 지출했습니다. 거래 후 Silvercape의 직접 보유 주식 수는 2,478,696주로 증가했습니다. 매도, 파생상품 거래 또는 Rule 10b5-1 계획 지정은 공개되지 않았습니다. 대규모 보유자의 이 정도 규모의 내부자 매수는 일반적으로 미래 전망에 대한 신뢰의 표시로 해석되며 주주 간의 일치를 강화합니다.

Résumé du formulaire 4 : Le 01/08/2025, Silvercape Investments Ltd—classée comme détentrice de 10 % de PetMed Express (PETS)—a acheté 118 200 actions ordinaires à 3,21 $, pour un investissement d'environ 379 000 $. Suite à cette opération, la participation directe de Silvercape s'élève à 2 478 696 actions. Aucune vente, transaction sur dérivés ou désignation de plan selon la règle 10b5-1 n'a été divulguée. Un achat d'initié de cette ampleur par un grand actionnaire est généralement interprété comme un signe de confiance dans les perspectives futures et renforce l'alignement avec les actionnaires.

Formular 4 Übersicht: Am 01.08.2025 kaufte Silvercape Investments Ltd—eingestuft als 10%-Eigentümer von PetMed Express (PETS)—118.200 Stammaktien zum Preis von 3,21 $, was einen Aufwand von etwa 379.000 $ bedeutet. Nach dem Handel steigt Silvercapes Direktbeteiligung auf 2.478.696 Aktien. Es wurden keine Verkäufe, Derivatgeschäfte oder Regel 10b5-1 Planbezeichnungen offengelegt. Insider-Käufe dieser Größenordnung durch einen Großaktionär werden typischerweise als Vertrauensbeweis in die zukünftigen Aussichten gewertet und stärken die Aktionärsausrichtung.

0001792781FALSE00017927812025-08-012025-08-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 1, 2025
Torrid_Logo_Black1.jpg
TORRID HOLDINGS INC.
(Exact name of registrant as specified in its charter)
Delaware001-4057184-3517567
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
18501 East San Jose Avenue
City of Industry, California 91748
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (626) 667-1002
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01CURVNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).    

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 1.01 Entry into a Material Definitive Agreement.
On August 1, 2025, Torrid LLC, a California limited liability company, entered into that certain Fifth Amendment to Amended and Restated Credit Agreement (“Amendment No. 5”) with Bank of America, N.A., as administrative agent and collateral agent (in such capacity, including any successor thereto, the “Agent”), and the lenders party thereto, which amends the Amended and Restated Credit Agreement, dated as of October 23, 2017 (such agreement as amended from time to time prior to the effectiveness of Amendment No. 5, the “Existing ABL Facility” and as amended by Amendment No. 5, the “Amended ABL Facility”).
Amendment No. 5 primarily extended the maturity date of the Existing ABL Facility from June 14, 2026 to the earlier of (i) August 1, 2030 and (ii) the date that is ninety-one (91) days prior to the maturity of any Material Indebtedness (as defined in the Existing ABL Facility). There are no other material changes to the other terms of the Existing ABL Facility.
The foregoing description of Amendment No. 5 does not purport to be complete and is qualified in its entirety by reference to Amendment No. 5, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03 of this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.

Exhibit No.Exhibit Description
10.1
Fifth Amendment to Amended and Restated Credit Agreement, dated August 1, 2025, among Torrid LLC, Bank of America, N.A., as administrative agent and collateral agent, and the lenders party thereto.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
TORRID HOLDINGS INC.
By:/s/ Bridgett C. Zeterberg
Name:Bridgett C. Zeterberg
Title:Chief Human Resources Officer, Chief Legal Officer and Corporate Secretary
Date: August 4, 2025
 

Torrid Hldgs Inc

NYSE:CURV

CURV Rankings

CURV Latest News

CURV Latest SEC Filings

CURV Stock Data

247.60M
17.63M
7.18%
78.64%
2.3%
Apparel Retail
Retail-apparel & Accessory Stores
Link
United States
CITY OF INDUSTRY